NCT04858958 2025-11-19
FAVOUR
Allist Pharmaceuticals, Inc.
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT02973763 2025-04-03
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04958967 2025-03-14
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Allist Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT05222087 2024-08-15
PRIME_LUNG
Peter MacCallum Cancer Centre, Australia
Phase 1 Recruiting
NCT06362980 2024-07-10
EGFR
National Cancer Center, China
Phase 1 Recruiting
NCT05615142 2024-04-17
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
Sichuan University
Phase 1 Recruiting
NCT04204473 2023-11-18
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
TYK Medicines, Inc
Phase 1 Completed
NCT05693090 2023-03-06
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Kura Oncology, Inc.
Phase 1 Withdrawn
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown